Krystal Biotech Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Krystal Biotech Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 02 Nov 2021 | Lorem |
| LoA Update: Krystal’s topical gene therapy approval shot in epidermolysis bullosa bolstered by Phase III follow-up completion | 02 Nov 2021 | Reynald Castaneda |
| Krystal’s KB103 splits experts' thoughts on potential for HSV-1 risk in dystrophic epidermolysis bullosa patients, but final Phase I/II efficacy assured | 07 Nov 2018 | Arafa Salam |
| Krystal to recruit two more adult patients on four-patient Phase I/II DEB trial of topical gene therapy, considers eye and fused hand clinical studies in 2019, sources say | 01 Nov 2018 | Arafa Salam |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer